---
id: HACEK-organisms_080
category: organisms
tags: [HACEK, Aggregatibacter, Haemophilus, Cardiobacterium, Eikenella, Kingella, endocarditis, ceftriaxone]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## HACEK Organisms

**Q:** What are the HACEK organisms, their clinical syndromes (especially endocarditis), and treatment strategies?

**A:**

**Definition:**
- **HACEK:** Acronym for group of **fastidious Gram-negative bacilli** causing endocarditis
- **Historically "culture-negative"** (required prolonged incubation >5 days)
- **Modern blood culture systems:** Detect within 5-7 days (no longer truly "culture-negative")

---

**HACEK Organisms:**

| **Letter** | **Organism** |
|------------|--------------|
| **H** | ***Haemophilus* species** (*H. parainfluenzae*, *H. aphrophilus*, *H. paraphrophilus*) |
| **A** | ***Aggregatibacter* species** (*A. actinomycetemcomitans*, *A. aphrophilus*) |
| **C** | ***Cardiobacterium hominis*** |
| **E** | ***Eikenella corrodens*** |
| **K** | ***Kingella kingae*** |

**Key Point:** ***Haemophilus influenzae* is NOT part of HACEK** (rarely causes endocarditis)

---

**Microbiology:**

**Shared Characteristics:**
- **Gram-negative bacilli** (sometimes coccobacilli)
- **Slow-growing** (historically required ≥2-3 weeks; modern systems 5-7 days)
- **Fastidious** (require enriched media - chocolate agar, blood culture bottles)
- **Part of oral/oropharyngeal flora**

---

## EPIDEMIOLOGY

**Incidence:**
- **3-10% of all IE cases** (historically; declining with modern diagnostics)
- **More common in older adults** (50-70 years)
- **Male predominance** (2-3:1)

**Risk Factors:**
- **Poor dentition / dental procedures**
- **Periodontal disease**
- **IV drug use** (rare compared to S. aureus)
- **Pre-existing valvular disease**

---

## CLINICAL SYNDROMES

---

### **1. Infective Endocarditis (MOST COMMON)**

**Characteristics:**
- **Indolent, subacute course** (weeks to months of symptoms)
- **Large vegetations** common (>10 mm)
- **High embolic rate** (28-71% - higher than other IE)
- **Both native and prosthetic valves**

**Clinical Features:**
- **Fever** (low-grade, insidious)
- **New murmur** (50-80%)
- **Heart failure** (30-40% - large vegetations → valve dysfunction)
- **Embolic events** (CNS, spleen, kidneys) - VERY COMMON

**Valves Affected:**
- **Aortic valve > mitral valve** (similar to viridans strep)
- **Both left-sided and right-sided** (tricuspid in IVDU)

**Key Point:** **HACEK IE = large vegetations + high embolic rate** (up to 71%)

---

### **2. Native Valve vs. Prosthetic Valve Endocarditis**

**Native Valve (More Common):**
- Subacute presentation
- Large vegetations
- Favorable prognosis if treated

**Prosthetic Valve:**
- More aggressive
- Higher mortality
- Often requires surgery

---

### **3. Other Infections (RARE)**

**Brain Abscess:**
- Rare, but reported
- Often polymicrobial (with oral anaerobes)

**Osteomyelitis:**
- ***Kingella kingae*** in children (most common cause of pediatric septic arthritis <5 years)
- ***Eikenella corrodens*** in human bite wounds ("clenched fist injury")

**Soft Tissue Infections:**
- ***Eikenella corrodens*** (human bites, IVDU)

**Pneumonia:**
- Very rare

---

## ORGANISM-SPECIFIC FEATURES

---

### ***Haemophilus* species (H. parainfluenzae)**

**Key Features:**
- **Most common HACEK organism** (50% of HACEK IE)
- Oropharyngeal flora
- **Large vegetations, high embolic rate**

**Resistance:**
- **β-lactamase production** possible (10-30%)
- **Ampicillin resistance** increasing

---

### ***Aggregatibacter actinomycetemcomitans***

**Key Features:**
- **Periodontal pathogen** (causes aggressive periodontitis)
- Associated with **dental disease**
- **High embolic rate** (up to 50%)
- Can cause **periodontal abscesses**

**Unique Virulence Factor:**
- **Leukotoxin** (kills white blood cells)

---

### ***Cardiobacterium hominis***

**Key Features:**
- **Oropharyngeal flora**
- **Very indolent course** (symptoms for months)
- **Large vegetations**

**Gram Stain:**
- **"Rosette" or "teardrop" appearance** (Gram-negative coccobacilli in clusters)

---

### ***Eikenella corrodens***

**Key Features:**
- **Oropharyngeal flora**
- **Human bite wounds** ("clenched fist injury" - punching someone in the mouth)
- **"Pitting colonies"** on agar (corrodes/pits the agar surface)
- **Bleach smell** (hypochlorite odor)

**Clinical Associations:**
- **Human bite infections** (ALWAYS cover Eikenella + oral anaerobes)
- **IVDU-associated infections** (endocarditis, septic arthritis, osteomyelitis)

**Antimicrobial Resistance:**
- **Intrinsically resistant to clindamycin, metronidazole**

---

### ***Kingella kingae***

**Key Features:**
- **#1 cause of septic arthritis and osteomyelitis in children <5 years**
- **Adults:** Rare cause of endocarditis
- **Oropharyngeal flora**

**Clinical Syndromes:**
- **Pediatric septic arthritis / osteomyelitis** (classic)
- **Adult endocarditis** (rare)

---

## DIAGNOSIS

---

**Blood Cultures:**

**Historical Challenge:**
- Required **prolonged incubation** (≥2-3 weeks)
- Often labeled "culture-negative endocarditis"

**Modern Systems (2010s Onward):**
- **Automated blood culture systems** detect HACEK within **5-7 days**
- **No longer truly "culture-negative"**

**Key Point:** **Hold blood cultures ≥5-7 days** (historically ≥3 weeks, but modern systems faster)

---

**Growth Requirements:**
- **Chocolate agar** (blood agar less reliable)
- **CO2-enriched atmosphere** (5-10% CO2)

---

**Molecular Diagnostics:**
- **16S rRNA gene sequencing** (if culture-negative but high suspicion)
- **MALDI-TOF** mass spectrometry (rapid identification)

---

**Echocardiography:**

**TEE Preferred:**
- **Large vegetations** (often >10 mm)
- TEE sensitivity 90-100% (TTE may miss)

---

## TREATMENT

---

### **Infective Endocarditis (Native Valve)**

**First-Line:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Ceftriaxone** (preferred) | 2g IV/IM q24h | **4 weeks** |

**Alternative:**
- **Ampicillin-sulbactam** 3g IV q6h x 4 weeks (if β-lactamase negative)
- **Cefotaxime** 2g IV q8h x 4 weeks
- **Ciprofloxacin** 400 mg IV q12h OR 750 mg PO BID x 4 weeks (if β-lactam allergy)

**Key Point:** **Ceftriaxone = first-line** (once-daily dosing, excellent efficacy)

---

### **Prosthetic Valve Endocarditis**

**First-Line:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Ceftriaxone** | 2g IV/IM q24h | **6 weeks** |

---

### **Rationale for Ceftriaxone:**
- **100% susceptible** (no resistance reported)
- **Excellent CSF penetration** (important if CNS emboli)
- **Once-daily dosing** (convenient for outpatient parenteral therapy)
- **Superior to ampicillin** (due to β-lactamase production in 10-30%)

---

### **Adjunctive Gentamicin? (NOT Recommended)**

**IDSA 2015:**
- **Do NOT add gentamicin routinely** for HACEK IE
- No clear benefit
- ↑ Nephrotoxicity

---

### **Non-Endocarditis Infections**

***Eikenella corrodens* (Human Bite Wound):**

**First-Line:**
- **Amoxicillin-clavulanate** 875 mg PO BID OR 2g IV q6h
- **PLUS** wound care (irrigation, debridement)

**Duration:** 7-14 days (depends on severity)

**Key Point:** **ALWAYS cover Eikenella + oral anaerobes** for human bites

---

***Kingella kingae* (Pediatric Septic Arthritis):**

**First-Line:**
- **Ceftriaxone** 50 mg/kg IV q24h OR **Cefazolin** 100 mg/kg/day IV divided q8h
- **PLUS** joint drainage

**Duration:** 3-4 weeks

---

## ANTIMICROBIAL RESISTANCE

**β-Lactamase Production:**
- **10-30% of HACEK organisms** produce β-lactamase
- Confers **ampicillin resistance**

**Current Susceptibility:**
- **Ceftriaxone:** 100% susceptible (NO resistance reported)
- **Ampicillin-sulbactam:** Active (sulbactam inhibits β-lactamase)
- **Fluoroquinolones:** 90-95% susceptible

**Key Point:** **NO ceftriaxone resistance** (unlike other GNRs)

---

## SURGICAL INDICATIONS

**HACEK IE Often Requires Surgery (40-60%):**

**Class I Indications:**
- **Heart failure** (large vegetation → valvular dysfunction)
- **Perivalvular abscess**
- **Recurrent emboli** despite antibiotics
- **Prosthetic valve IE**
- **Large vegetation >10 mm** (especially if embolic event)

**Key Point:** **High embolic rate (28-71%)** → Surgery often needed to prevent further emboli

---

## OUTCOMES & PROGNOSIS

**With Appropriate Treatment:**
- **Cure rate: 85-95%** (favorable prognosis)
- **Mortality: 5-15%** (lower than S. aureus IE)

**Predictors of Poor Outcome:**
- **Prosthetic valve IE**
- **Heart failure**
- **CNS complications** (embolic stroke, abscess)
- **Delayed diagnosis**

**Key Point:** **HACEK IE has BETTER prognosis** than S. aureus or fungal IE (if treated appropriately)

---

## EMBOLIC COMPLICATIONS

**High Embolic Rate (28-71%):**

**Common Sites:**
- **CNS:** Embolic stroke, mycotic aneurysm, brain abscess
- **Spleen:** Splenic infarct/abscess
- **Kidneys:** Renal infarct
- **Coronary arteries:** Myocardial infarction (rare)

**Prevention:**
- **Early antibiotic therapy**
- **Surgery** if large vegetation (>10 mm) + embolic event

---

**Mnemonic: "HACEK = Heart Attacks Cause Embolic Khaos"**
- **H**eart valves (endocarditis #1 syndrome)
- **A**ggressive vegetation growth (large vegetations)
- **C**eftriaxone = first-line treatment
- **E**mbolic rate HIGH (28-71%)
- **K**ingella = kids' septic arthritis

**Mnemonic: "Eikenella = Human Bites (Clenched Fist)"**
- **E**ikenella corrodens
- **C**lenched fist injury (punching someone in mouth)
- **H**uman bite wound (ALWAYS cover Eikenella + anaerobes)

**Mnemonic: "Kingella = Kids"**
- **K**ingella kingae
- **K**ids' septic arthritis (<5 years old)

**Clinical Pearls:**
- **HACEK = 3-10% of all IE** (declining with modern diagnostics)
- **Indolent, subacute course** (weeks to months of symptoms)
- **Large vegetations common** (>10 mm)
- **HIGH embolic rate (28-71%)** - higher than other IE
- **Ceftriaxone 2g IV q24h x 4 weeks = first-line** (NVE), 6 weeks (PVE)
- **100% susceptible to ceftriaxone** (NO resistance reported)
- **Do NOT add gentamicin** routinely (no clear benefit)
- **Modern blood culture systems detect within 5-7 days** (no longer "culture-negative")
- **β-lactamase production in 10-30%** → ampicillin resistance
- **Surgery often needed** (40-60%) - large vegetations, high embolic rate
- **Favorable prognosis** (85-95% cure rate, 5-15% mortality)
- **Eikenella corrodens:** Human bites, "pitting colonies," bleach smell
- **Kingella kingae:** #1 cause of pediatric septic arthritis <5 years
- **Aggregatibacter:** Periodontal disease, leukotoxin
- **Cardiobacterium:** "Rosette" appearance on Gram stain

**Media:** None

**Sources:** [IDSA 2015 - Infective Endocarditis Guidelines], [PMC 2024 - HACEK endocarditis review], [Clinical Microbiology Reviews 2023 - HACEK organisms], [AHA 2021 - Culture-negative endocarditis], [Journal of Infection 2024 - HACEK IE outcomes]
